文献速递慢阻肺

FEV3/FEV6 在识别吸烟者早期气道疾病中的意义:SPIROMICS 队列分析

Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.
PubMed 文献 · Chest · 2021-11-10

该研究基于 SPIROMICS 队列中 832 名支气管舒张后 FEV1/FVC≥0.7 的现吸烟者与既往吸烟者,评估 FEV3/FEV6 低于正常下限(LLN)与早期气流异常及临床结局的关系。结果显示,FEV3/FEV6 降低与更差肺功能、更多肺气肿及功能性小气道疾病相关,并可预测一年内重度急性加重和后续 COPD 发生。

要点

  • FEV3/FEV6 是常规可得的重复性好的肺功能指标,可用于识别无 COPD 吸烟者的早期气流阻塞。
  • FEV3/FEV6 低于 LLN 与更差肺功能、更多肺气肿及功能性小气道疾病相关。
  • FEV3/FEV6 降低可预测一年内重度呼吸道急性加重及后续 COPD 发生。

核心结论

  • FEV3/FEV6 是常规可得且重复性好的肺功能指标,可用于评估无 COPD 的现吸烟者与既往吸烟者的早期气流阻塞。
  • FEV3/FEV6 降低可识别未来发生 COPD 和呼吸道急性加重风险较高的个体。

研究设计与样本

  • 研究纳入 SPIROMICS 队列中 832 名支气管舒张后 FEV1/FVC≥0.7 的现吸烟者与既往吸烟者。
  • 根据正常下限(LLN)将参与者分为支气管舒张前 FEV3/FEV6 降低组与不低于 LLN 组。
  • 对 FEV3 和 FEV6 进行重复性分析,采用回归模型评估基线 FEV3/FEV6 与影像学功能性小气道疾病及呼吸道急性加重等结局的关系。
  • 采用区间删失分析评估向 COPD 的进展。

主要发现

  • 基线 FEV3/FEV6 低于 LLN 与更低的 FEV1、更差健康状况(圣乔治呼吸问卷评分)、更多肺气肿及更多定量影像功能性小气道疾病相关。
  • FEV3 和 FEV6 重复测量间一致性极好。
  • FEV3/FEV6 降低与随访第一年内重度呼吸道急性加重风险增加及首次急性加重时间缩短相关。
  • FEV3/FEV6 降低还与随访期间根据肺功能结果(支气管舒张后 FEV1/FVC<0.7)诊断的 COPD 发生相关。

关键数值与推荐

  • FEV3/FEV6 降低定义为低于正常下限(LLN)。
  • COPD 发生定义为支气管舒张后 FEV1/FVC<0.7。

临床怎么用

  • 在无 COPD 的现吸烟者与既往吸烟者中,可考虑计算 FEV3/FEV6 以辅助识别早期气流阻塞。
  • FEV3/FEV6 降低提示未来 COPD 及呼吸道急性加重风险较高,可加强随访与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Small airways are known to be affected early in the course of COPD; however, traditional spirometric indices may not accurately identify small airways disease. RESEARCH QUESTION: Can forced expiratory volume in 3 s/forced expiratory volume in 6 s (FEV3/FEV6) identify early airflow abnormalities and predict future clinically important respiratory-related outcomes, including development of COPD? STUDY DESIGN AND METHODS: The study included 832 current and former smokers with post-bronchodilator FEV1/FVC ≥ 0.7 from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort. Participants were classified as having a reduced pre-bronchodilator FEV3/FEV6 based on lower limit of normal (LLN) values. Repeatability analysis was performed for FEV3 and FEV6. Regression modeling was used to evaluate the relationship between baseline FEV3/FEV6 and outcome measures, including functional small airways disease, on thoracic imaging and respiratory exacerbations. Interval-censored analysis was used to assess progression to COPD. RESULTS: FEV3/FEV6 less than the LLN at baseline, defined as reduced compared with FEV3/FEV6 at or above the LLN, was associated with lower FEV1, poorer health status (St. George's Respiratory Questionnaire score), more emphysema, and more functional small airways disease on quantitative imaging. FEV3 and FEV6 showed excellent agreement between repeat measurements. A reduced FEV3/FEV6 was associated with increased odds of a severe respiratory exacerbation within the first year of follow-up and decreased time to first exacerbation. A low FEV3/FEV6 was also associated with development of COPD according to spirometry results (post-bronchodilator FEV1/FVC < 0.7) during study follow-up. INTERPRETATION: FEV3/FEV6 is a routinely available and repeatable spirometric index that can be useful in the evaluation of early airflow obstruction in current and former smokers without COPD. A reduced FEV3/FEV6 can identify those at risk for future development of COPD and respiratory exacerbations. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov: ClinicalTrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Yee, Markovic, Buhr, et al. Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort. Chest. 2021. PMID: 34767825. doi:10.1016/j.chest.2021.10.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。